Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo

British Journal of Cancer

Volumn 74, Issue 7, 1996, Pages 1023-1029

  Vingerhoeds, M H ^a,b   Steerenberg, P A ^b   Hendriks, J J G W ^b   Dekker, L C ^a,b   Van Hoesel, Q G C M ^c   Crommelin, D J A ^a,b   Storm, G ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Doxorubicin; Immunoliposome; Monoclonal antibody; Ovarian cancer; Targeted drug delivery

Indexed keywords

DOXORUBICIN; IMMUNOLIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFECT; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PHARMACEUTICS; PHARMACOLOGY; PRIORITY JOURNAL; TUMOR CELL;

EID: 0029785716     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.484     Document Type: Article

References (30)

1. BOERMAN O, MASSUGER L, MAKKINK K, THOMAS C, KENEMANS P AND POELS L. (1990). Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies. Anti-cancer Res., 10, 1289-1296.
2. DELGADO G, POTKUL RK, TREAT JA, LEWANDOWSKI GS, BARTER JF, FORST D AND RAHMAN A. (1989). A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. Am. J. Obstet. Gynecol., 160, 812-819.
3. DEPPE G, MALVIYA V, DECKER D, EVANS L, YOUNG J AND SCHILCHER B. (1985). A preliminary report on the toxicity and pharmacokinetics of combination systemic and intraperitoneal chemotherapy in advanced epithelial ovarian cancer. Gynecol, Oncol., 20, 269.
4. FISKE CH AND SUBBAROW Y. (1925). The colorimetric determination of phosphorus. J. Biol. Chem., 66, 375-400.
5. FORSSEN EA AND TOKES ZA. (1981). Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc. Natl Acad. Sci. USA. 78, 1873-1877.
6. HAMILTON TC, YOUNG RC, MCKOY WM, GROTZINGER KR, GREEN JA, CHU EW, WHANG-PENN J, ROGAN AM, GREEN WR AND OZOLS RF. (1983). Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res., 43, 5379-5389.
7. HAMILTON TC, YOUNG RC, LOUIE KG, BEHRENS BC, MCKOY WM, GROTZINGER KR AND OZOLS RF. (1984). Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res., 44, 5286-5290.
8. HARAN G, COHEN R, BAR LK AND BARENHOLZ Y. (1993). Transmembrane ammonium sulphate gradients in liposomes produce efficient and stable entrapment of amphiphatic weak bases. Biochim. Biophys. Acta, 1151, 201-205.
9. MARKMAN M. (1991). Intraperitoneal chemotherapy. Semin. Oncol., 18, 248-254.
10. MARKMAN M, HAKES T, REICHMAN B, HOSKINS W, RUBIN S, JONES W, ALMADONES L AND LEWIS JL. (1989). Intraperitoneal therapy in the management of ovarian carcinoma. Yale J. Biol. Med., 62, 393-403.
11. MARTIN FJ AND PAPAHADJOPOULOS D. (1982). Irreversible coupling of immunoglobulin fragments to preformed vesicles. J. Biol. Chem., 257, 286-288.
12. MARUYAMA K, UNEZAKI S, TAKAHASHI N AND IWATSURU M. (1993). Enhanced delivery of doxorubicin to tumour by long-circulating thermosensitive liposomes and local hyperthermia. Biochim. Biophys. Acta, 1149, 209-216.
13. MASSUGER LFAG, KENEMANS P, CLAESSENS RAMJ, VERHEIJEN RHM AND CORSTENS FHM. (1991). Detection and localization of ovarian cancer with radiolabelled monoclonal antibodies. Eur. J. Obstet. Gynecol. Reprod. Biol., 41, 47-63.
14. 2 fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenografts. Int. J. Cancer, 42, 368-372.
15. NÄSSANDER UK, STEERENBERG PA, POPPE H, STORM G, POELS LG, DE JONG WH AND CROMMELIN DJA. (1992). In vivo targeting of OV-TL3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. Cancer Res., 52, 646-653.
16. NÄSSANDER UK, STEERENBERG PA, DE JONG WH, VAN OVERVELD WOWM TE, BOEKHORST CME. POELS LG, JAP PHK AND STORM G. (1995). Design of immunoliposomes directed against human ovarian carcinoma. Biochim. Biophys. Acta, 1235, 126-139.
17. OZOLS RF, YOUNG RC, SPEYER JL, SUGARBAKER PH, GREENE R, JENKINS J AND MYERS CE. (1982). Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res., 42, 4265-4269.
18. POELS LG, PETERS D, VAN MEGEN Y, VOOIJS GP, VERHEYEN RNM. WILLEMEN A, VAN NIEKERK CC, JAP PHK, MUNGYER G AND KENEMANS P. (1986). Monoclonal antibody against human ovarian tumor-associated antigens. J. Natl Cancer Inst., 76, 781-791.
19. POOL GL, FRENCH ME, EDWARDS RA, HUANG L AND LUMB RH. (1982). Use of radiolabeled hexadecyl cholesteryl ether as a liposome marker. Lipids, 17, 445-452.
20. RUBINSTEIN LV, SHOEMAKER RH, PAULL KD, SIMON RM, SKEHAN P, SCUDIERO DA, MONKS A AND BOYD MR (1990). Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl Cancer Inst., 82, 1113-1118.
21. RYGAARD J AND FRIIS CW. (1974). The husbandry of mice with congenital absence of the thymus (nude mice). Z. Versuchstierk. Bd., 16, 1-10.
22. SINGH M, GHOSE T, MEZEI M AND BELITSKY P. (1991). Inhibition of human renal cancer by monoclonal antibody targeted methotrexate-containing liposomes in an ascites tumour model. Cancer Lett., 56, 97-102.
23. SKEHAN P, STORENG R, SCUDIERO DA, MONKS A, MCMAHON J, VISTICA D, WARREN JT, BOKESH H, KENNEY S AND BOYD MR. (1990). New colorimetric cytotoxicity assay for anticancer-drug-screening. J. Natl Cancer Inst., 82, 1107-1112.
24. 3H]cholesteryl oleyl ether in cultured fibroblasts and intact rat. FEBS Lett., 111, 104-106.
25. STORM G, VAN BLOOIS L, BROUWER M AND CROMMELIN DJA. (1985). The interaction of cytostatic drugs with adsorbents in aqueous media. Biochim. Biophys. Acta, 818, 343-351.
26. STRAUBINGER RM, LOPEZ NG, DEBS RJ. HONG K AND PAPAHADJOPOULOS D. (1988). Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res., 48, 5237-5245.
27. TORCHILIN VP, ZHOU F AND HUANG L. (1993). pH-sensitive liposomes. J. Lipid Res., 3, 201-255.
28. WESSEL D AND FLÜGGE UI. (1984). A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal. Biochem., 138, 141-143.
29. WISH L, FURTH J AND STOREY RH, (1950). Direct determination of plasma cell and organ-blood volumes in normal and hypervolemic mice. Proc. Soc. Exp. Biol. N. Y., 74, 644-648.
30. YATVIN MB, WEINSTEIN JN, DENNIS WH AND BLUMENTHAL R. (1978). Design of liposomes for enhanced local release of drugs by hyperthermia. Science, 202, 1290-1293.